Cadila Healthcare Ltd board approved amalgamation of German Remedies Ltd, Recon Healthcare Ltd, Zydus Pathline Ltd & Zoom Properties Ltd with the company.
Cadila Healthcare to seek nod for amalgamation
A meeting of the board of Cadila Healthcare Ltd will be held on January 29 to consider the quarterly results for the third quarter ended December 31, 2002.
German Remedies to merge with Cadila Healthcare
Cadila Healthcare Ltd has posted a net profit of Rs 172.91 million for the quarter ended December 31, 2002 as compared to Rs 147.03 million for the quarter ended December 31, 2001.
Acquisition of popular brands such as Complan, Glucon D, Nycil and Sampriti Ghee from Heinz India would be a part of the deal, Cadila Healthcare said in a filing to BSE.
Cadila Healthcare Ltd has received tentative approval from US FDA to market its antibiotic, Gatifloxacin tablets, 200 mg and 400 mg, in the US market.
Approval was given by the United States Food and Drug Administration for an investigational new drug application for ZYGK1, Cadila Healthcare said in a filing to the Bombay Stock Exchange.
The company said the drug will be made available across India through the group's strong distribution chain reaching out to government and private hospitals treating COVID-19 patients.
Cadila Healthcare Ltd said on Thursday, said German Remedies, a part of the Zydus Group, has launched Fludara Oral (Fludarabine) in the Indian market for the treatment of chronic lymphocytic leukemia.
Cadila Healthcare Ltd has received approval from USFDA for marketing anti-coagulant, Warfarin tablets.
Cadila Healthcare Ltd has announced that Zydus Cadila has received its very first approval from USFDA to market Atenolol, an anti-hypertensive drug, in the US market.
Drug firm Zydus Cadila on Thursday said it has applied for emergency use authorisation (EUA) with the Indian drug regulator for its three-dose COVID-19 vaccine ZyCoV-D, and plans to manufacture 10-12 crore doses annually.
Pharma major Cadila Healthcare Ltd plans to invest Rs 40 crore (Rs 400 million) to acquire stake in a Europe-based biotech company.
The regulator has given the company 15 days to take corrective measures and report back to it.
Cadila Healthcare Ltd has received tentative approval from the USFDA to market Pravastatin Sodium Tablets in the US market.
Can Interferon alfa-2b treat COVID-19 effectively?
Sources say FDA letter over product and not entire facility
Cadila Health, to merge with German Remedies
Cadila Healthcare Ltd has posted a net profit of Rs 39.43 crore for the second quarter ended September 30, 2003, compared to Rs 30.28 crore recorded in the same period last fiscal.
Cadila Healthcare Ltd on Monday said it has received tentative approval from the US FDA to market Levofloxacin tablets of 250 mg, 500 mg and 750 mg in the US market.
Cadila Healthcare on Friday said it had received permission to conduct clinical trials on its new molecular entity - ZYH1 - a formula to check cholesterol in blood. The drug controller general of India gave its approval to conduct phase I clinical tr
Zydus Cadila Healthcare Ltd on Tuesday said it has received approval from the French regulatory agency, AFSSAPS, to market Sertraline capsules 25 mg and 50 mg, in the French market.
Zydus Cadila Healthcare on Monday said its net profit during 2003-04 increased by 86.68 per cent to Rs 143 crore (Rs 1,430 million) as against Rs 76.6 crore (Rs 766 million) in the previous year.
This could also be India's first vaccine for children aged 12 years and above as the company has conducted trials on the age group. The decision, however, lies with the regulator, reports Sohini Das
While Bharat Biotech's Covaxin is in trials among children already, Serum Institute of India will begin Novavax vaccine trials on children from July, whereas the Pfizer vaccine has been approved for adolescents in the United States; and Cadila Healthcare's ZyCoV-D has done trials on 12 year-olds and above already, reports Sohini Das.
So far, no other vaccine has been approved globally for children below 12 years. Sohini Das reports.
The government has also given permission to 20 plants to produce the antiviral drug.
This government's approval for use of the antiviral drug comes at a time when India's daily COVID tally is crossing the 3-lakh mark.
Companies such as Cadila Healthcare, Lupin, and Natco, which sell generic versions of flu medication in the US market, are likely to benefit.
The rupee's appreciation of 6.4 per cent against the dollar and 12 per cent against the euro is likely to hurt the first-quarter performance of the pharmaceutical sector, indicate a results' preview by broking houses.
Zydus plans to initiate the clinical trials of ZyCoV-D in July 2020 across multiple sites in India. In animal studies the vaccine was found to elicit a strong immune response in multiple animal species like mice, rats, guinea pigs and rabbits.
German Remedies seeks nod for amalgamation with Cadila Healthcare
Responding to another question, Choubey said that the phase-I of clinical trials have revealed excellent safety of the two candidate vaccines indigenously developed by Bharat Biotech in collaboration with Indian Council of Medical Research and Cadila Healthcare Ltd, and now their immunogenicity testing is in progress. Their phase II clinical trials are ongoing.
The new drugs to come under price control include commonly-used antibiotics and painkillers
Indian government has extended price caps to 39 more medicines ranging from commonly used diabetes drugs to antibiotics.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances